beringer-pm - Search Results

Year	Number of Results
1995	1
1998	3
1999	1
2000	3
2001	1
2002	2
2003	1
2004	1
2005	2
2006	1
2008	3
2009	1
2010	1
2011	1
2012	3
2014	1
2015	2
2016	1
2017	2
2018	2
2019	2
2021	5
2022	3
2023	3
2024	3

1

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series.

Hong E, Li R, Shi A, Almond LM, Wang J, Khudari AZ, Haddad S, Sislyan S, Angelich M, Chung PS, Rao AP, Beringer PM. Hong E, et al. Pharmacotherapy. 2023 Apr;43(4):291-299. doi: 10.1002/phar.2786. Epub 2023 Mar 12. Pharmacotherapy. 2023. PMID: 36866442

2

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1.

Park AYJ, Tran DQ, Schaal JB, Wang M, Selsted ME, Beringer PM. Park AYJ, et al. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0212521. doi: 10.1128/aac.02125-21. Epub 2022 Jan 18. Antimicrob Agents Chemother. 2022. PMID: 35041507 Free PMC article.

3

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients.

Hong E, Carmanov E, Shi A, Chung PS, Rao AP, Forrester K, Beringer PM. Hong E, et al. Pharmaceutics. 2023 May 8;15(5):1438. doi: 10.3390/pharmaceutics15051438. Pharmaceutics. 2023. PMID: 37242680 Free PMC article.

4

Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features.

Beringer PM, Appleman MD. Beringer PM, et al. Curr Opin Pulm Med. 2000 Nov;6(6):545-50. doi: 10.1097/00063198-200011000-00015. Curr Opin Pulm Med. 2000. PMID: 11100967 Review.

5

Pharmacokinetics of Ibuprofen in children with cystic fibrosis.

Han EE, Beringer PM, Louie SG, Gill MA, Shapiro BJ. Han EE, et al. Clin Pharmacokinet. 2004;43(3):145-56. doi: 10.2165/00003088-200443030-00001. Clin Pharmacokinet. 2004. PMID: 14871154 Review.

6

Economic aspects of antibacterial adverse effects.

Beringer PM, Wong-Beringer A, Rho JP. Beringer PM, et al. Pharmacoeconomics. 1998 Jan;13(1 Pt 1):35-49. doi: 10.2165/00019053-199813010-00004. Pharmacoeconomics. 1998. PMID: 10175984 Review.

7

Transporters and their impact on drug disposition.

Beringer PM, Slaughter RL. Beringer PM, et al. Ann Pharmacother. 2005 Jun;39(6):1097-108. doi: 10.1345/aph.1E614. Epub 2005 May 10. Ann Pharmacother. 2005. PMID: 15886292 Review.

8

Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration.

Hong E, Parsons SM, Sass L, Epstein C, Chan L, Brown C, Eshaghian PH, Beringer PM. Hong E, et al. J Cyst Fibros. 2023 Nov 30:S1569-1993(23)01721-6. doi: 10.1016/j.jcf.2023.11.015. Online ahead of print. J Cyst Fibros. 2023. PMID: 38036321

9

Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis.

Beringer PM, Vinks AA, Jelliffe RW. Beringer PM, et al. J Antimicrob Chemother. 1998 Jan;41(1):142-4. doi: 10.1093/oxfordjournals.jac.a020865. J Antimicrob Chemother. 1998. PMID: 9511054 Review. No abstract available.

10

Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction.

Chaudhuri D, Ganesan R, Vogelaar A, Dughbaj MA, Beringer PM, Camarero JA. Chaudhuri D, et al. J Org Chem. 2021 Nov 5;86(21):15242-15246. doi: 10.1021/acs.joc.1c01858. Epub 2021 Oct 12. J Org Chem. 2021. PMID: 34641669 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

46 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year